Tag Archives: Cardiology

V Heart Failure 2020

Discount for SOLACI Members – V Heart Failure Review 2020

Discount for SOLACI Members – V Heart Failure Review 2020

On December 7 thru 12 SOLACI is holding the 5th International Round of Conferences 2020 on “Heart Failure and Pulmonary Hypertension: Management of hear failure in times of polypharmacy and artificial devices”.   The event will take place next week Monday thru Friday from 5 to 7 pm and Saturday 12 from 10 to 12 am

SOLACI-CACI 2021 Preliminary Agenda

Check out the main topics of the upcoming SOLACI-CACI 2021 Congress. Save the Date!   Special Session About the COVID-19 Pandemic   Managing Cardiovascular disease and Cath Lab during the COVID-19 Pandemic Live Case Transmissions Coronary and Structural cases performed by distinguished international and national operators. Coronary Track   Myocardial Infarction, Left Main session, Complex

Special Articles On COVID-19

Special Articles on COVID-19

Myocardial Injury for COVID-19 Even in Young Patients with Mild Symptoms Most young COVID-19 patients not requiring hospitalization showed abnormal cardiac magnetic resonance imaging (CMR) beyond two months after diagnosis. Read more HERE Infarction, Stroke and Aortic Emergency Syndromes in the Shadow of the Pandemic The coronavirus pandemic has had a negative impact on the

Most read scientific articles of may in interventional cardiology

The Most Read Scientific Articles of May in Interventional Cardiology

01- Management of Infarction During the COVID-19 Pandemic Patients with cardiovascular disease infected with COVID-19 are at a particular risk for morbidity and mortality. In any case, it should be noted that most patients requiring cardiovascular care due to ischemic heart disease, peripheral vascular disease, or structural heart disease are not infected. Read more HERE

implante de la valvula aortica transcateter

TAVR Reaches Low-Risk Patients with Bicuspid Valves

Transcatheter aortic valve replacement (TAVR) seems to be safe in low-risk patients with bicuspid aortic valve stenosis. Their hospital length of stay was very short, with zero mortality, and zero disabling stroke. Subclinical leaflet thrombosis and device durability are still unknown. The United States Food and Drug Administration (FDA) approved TAVR for low-risk patients. However,